RPRX
Royalty Pharma plcNASDAQHealthcare$48.57+0.16%ClosedMarket Cap: $20.81B
As of 2026-04-06
Valuation
P/E (TTM)
26.99
PEG
—
P/B
3.24
P/S
8.75
EV/EBITDA
17.83
DCF Value
$28.89
FCF Yield
12.0%
Div Yield
1.8%
Margins & Returns
Gross Margin
100.0%
Operating Margin
65.6%
Net Margin
32.4%
ROE
11.9%
ROA
4.1%
ROIC
8.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $622.0M | 100.0% | $388.4M | $214.2M | $0.50 | $0.22 |
| FY 2025 | $2.38B | 100.0% | $1.56B | $770.9M | $1.80 | $0.88 |
| Q3 2025 | $609.3M | 100.0% | $427.2M | $288.2M | $0.67 | $0.22 |
| Q2 2025 | $578.7M | 100.0% | $209.8M | $30.2M | $0.07 | $0.22 |
| Q1 2025 | $568.2M | 100.0% | $534.2M | $238.3M | $0.55 | $0.22 |
| Q4 2024 | $593.6M | 100.0% | $361.5M | $208.2M | $0.47 | $0.21 |
| FY 2024 | $2.26B | 100.0% | $1.29B | $859.0M | $1.45 | $0.84 |
| Q3 2024 | $564.7M | 100.0% | $735.1M | $544.0M | $0.92 | $0.21 |
| Q2 2024 | $537.3M | 100.0% | $269.6M | $102.0M | $0.23 | $0.21 |
| Q1 2024 | $568.0M | 100.0% | $-73.8M | $4.8M | $0.01 | $0.21 |
| Q4 2023 | $596.1M | 100.0% | $612.9M | $494.3M | $1.10 | $0.20 |
| FY 2023 | $2.35B | 100.0% | $1.49B | $1.13B | $2.53 | $0.80 |